- Oral presentation
- Open access
- Published:
Immune activation and MRgFUS
Journal of Therapeutic Ultrasound volume 3, Article number: O41 (2015)
Background/introduction
For many years, immune activation following tumor ablation has been evaluated in the treatment of systemic cancer. Ultrasound ablation is thought to promote dendritic cell maturation and T-cell immunity, and is particularly advantageous because it is non-invasive, can be controlled with high spatial precision and uses no harmful ionizing radiation.
Methods
Recently, immune adjuvants have been shown to be effective in treating metastatic cancer, with cancer immunotherapy named as the “breakthrough of the year” in 2013. At this time, combining ablation with immune adjuvants is a promising technique for expanding the utility of ultrasound for the treatment of systemic disease. We will briefly review the status of this combined therapy and opportunities for future studies.
Author information
Authors and Affiliations
Rights and permissions
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Ferrara, K., Ingham, E., Wong, A. et al. Immune activation and MRgFUS. J Ther Ultrasound 3 (Suppl 1), O41 (2015). https://doi.org/10.1186/2050-5736-3-S1-O41
Published:
DOI: https://doi.org/10.1186/2050-5736-3-S1-O41